A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10ng/ml at Initial Biopsy

• Published in: European urology Vol. 74; no. 6; pp. 731 - 738
• Main Authors: McKiernan, James, Donovan, Michael J., Margolis, Eric, Partin, Alan, Carter, Ballentine, Brown, Gordon, Torkler, Phillipp, Noerholm, Mikkel, Skog, Johan, Shore, Neal, Andriole, Gerry, Thompson, Ian, Carroll, Peter
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.12.2018
• Subjects: Exosomes; Extended validation study; High grade prostate cancer; Initial biopsy; Prostate cancer; Risk assessment tools; Initial biopsy; Risk assessment tools; Exosomes; Prostate cancer; High grade prostate cancer; Extended validation study
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2018.08.019

Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy. A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2–10ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. In a total of 503 patients, with median age of 64 yr, median PSA 5.4ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n=519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2–10ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data. ExoDx Prostate (IntelliScore) is a urine-based test that relies solely on a three-gene signature to predict high-grade prostate cancer at initial biopsy for men with prostate-specific antigen 2–10ng/ml. The test has been prospectively validated on over 1000 men from two multisite trials.